Syros’ CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies
Syros Pharmaceuticals Inc (NASDAQ: SYRS)
Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case
A jury in Marshall, Texas, awarded Seagen Inc (NASDAQ: SGEN)
Japan Canceled One-third of 120M Contracted Astrazeneca Vaccines
-Reuters
https://www.reuters.com/world/asia-pacific/japan-cancels-third-contracted-astrazeneca-vaccine-purchase-2022-04-11/
AstraZeneca Bets $25M On Preclinical Bispecific Antibody
Harbour BioMed has announced a global out-license agreement with AstraZeneca plc (NASDAQ:AZN) for CLDN18.2xCD3 bispecific antibody (HBM7022). HBM7022 is a novel bispecific…
What Is RSV, And Why Is Pfizer Paying Up To $525M For Treatment Candidates?
Pharma giant Pfizer, Inc. (NYSE: PFE), which has found huge success with its COVID franchise, is now looking to conquer another frontier.
FDA Official Says Frequent COVID-19 Booster Shows Not Sustainable: WSJ
According to a U.S. health regulator, asking people to get COVID-19 boosters frequently wasn't sustainable because of vaccine fatigue, and authorities needed to develop a long-term strategy for protection against the evolving virus.
Here’s How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years
AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 4.32% on an annualized basis producing an average annual return of 18.01%. Currently, AstraZeneca has a market capitalization of $214.04 billion.
AstraZeneca’s Ultomiris Shows Sustained Improvements In Functional Activities In Neuromuscular Disease
AstraZeneca Plc (NASDAQ:AZN) shared new and prolonged follow-up results from the Phase 3 CHAMPION-MG trial open-label extension (OLE) of Ultomiris (ravulizumab-cwvz)…
AstraZeneca Press Release From Very Early Monday Morning Showed Its AZD8233 Candidate Reduced Low-Density Lipoprotein Cholesterol Levels By 73% In Patients With High-Risk Hypercholesterolemia In Phase 3 Trial
https://www.astrazeneca.com/media-centre/press-releases/2022/azd8233-reduced-low-densi[…]high-risk-hypercholesterolemia-etesian-phase-iib-trial.html